A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02272855|
Recruitment Status : Completed
First Posted : October 23, 2014
Last Update Posted : September 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Malignant Melanoma||Biological: HF10 plus Ipilimumab||Phase 2|
The study is designed to assess efficacy and safety with repeated administration of intratumoral injections of HF10 at 1x10^7 TCID50/mL in combination with intravenous infusions of 3mg/kg ipilimumab. This is a single arm, open label Phase II trial, to evaluate the efficacy, safety and tolerability of HF10 treatment in combination with administration of the immunologic checkpoint inhibitor, ipilimumab (anti-CTLA-4 monoclonal antibody). The study population will include patients with Stage IIIB, IIIC or IV unresectable or metastatic malignant melanoma who are ipilimumab-eligible.
Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) + ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Following combination therapy, patients may continue to receive the same dose level of HF10 (1 x 10^7 TCID50/mL) alone for up to an additional 13 injections (total of 19 injections = 1 year) if they have tolerated the study treatment, are responding, have stable disease, or have progressive disease that is not clinically significant in the judgment of the Investigator.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Combination Treatment With HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients With Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma|
|Actual Study Start Date :||April 30, 2014|
|Actual Primary Completion Date :||October 2016|
|Actual Study Completion Date :||August 2018|
|Experimental: HF10 plus ipilimumab||
Biological: HF10 plus Ipilimumab
Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Other Name: YERVOY (for ipilimumab)
- Best overall response rate (BORR) [ Time Frame: at 24 weeks ]
- Adverse Event Summaries, Vital Signs, and Laboratory Parameters as a Measure of Safety and Tolerability [ Time Frame: until Week 24 ]Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).
- Objective response rate (ORR) [ Time Frame: at Weeks 12, 18, and 24 ]
- Progression-free survival (PFS) [ Time Frame: for 1 year ]
- Durable response rate (DRR) [ Time Frame: for 1 year ]
- 1-year survival rate [ Time Frame: at 1 year ]
- Accumulation of Lymphocytes in the Tumor by using Core Biopsy Samples [ Time Frame: pre-treatment screening and Week 24 ]
- Change in Cytokine Profiles by using Peripheral Blood Samples [ Time Frame: pre-treatment screening and Week 24 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02272855
|United States, California|
|San Francisco, California, United States, 94115|
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|United States, Oregon|
|Portland, Oregon, United States, 97239|
|United States, Pennsylvania|
|Bethlehem, Pennsylvania, United States, 18015|
|Hershey, Pennsylvania, United States, 17033|
|United States, Texas|
|Dallas, Texas, United States, 75230|
|Houston, Texas, United States, 77030|
|United States, Utah|
|Salt Lake City, Utah, United States, 84112|
|Principal Investigator:||Robert Andtbacka||University of Utah|